eng
  • kor
  • eng
  • chn
  • esp
topBtn
News
News

Vieworks Posts 74% Jump in Q2 Operating Profit, Signals Profitability Recovery

2025-08-05

 

Vieworks reported Q2 consolidated sales of 62.7 billion won ($45.6 million) and operating profit of 6.5 billion won, up 15.6% and 73.9% year over year. Compared with Q1, sales rose 15.3% and operating profit jumped 217.2%, driven by a stronger product mix and lower operating costs.

Static Detectors — Sales reached 27.6 billion won, up 7.2% from last year, with steady demand for high value-added models in North America and Europe. CE MDR certification renewal is in progress. company is also boosting its competitiveness in key bidding markets by combining proprietary software with AI-based noise reduction technology.
 

Dynamic Detectors — Sales fell 21.7% to 7.9 billion won on temporary weakness in the global dental system market. The company described the decline as a short-term adjustment following annual growth averaging 46% from 2018, when the product was launched, through 2024. Orders from major customers are expected to resume in the second half.

 

Industrial Detectors (Non-Destructive Testing) — Sales surged 114.6% to 7.9 billion won. Growth was fueled by expanded orders in the portable security and pipe inspection markets. New bendable detector products demonstrated competitiveness in bidding, creating fresh demand. Sales of 3D CT dynamic detectors for battery manufacturing also continue to grow gradually, particularly among domestic customers.
 

Industrial Imaging Solutions — Machine vision solution sales grew 10.3% to 12.3 billion won. Global supply chain stabilization and rising demand for equipment replacement in industries such as displays, semiconductors and secondary batteries are driving growth.
 

New Business — The VISQUE DPS digital pathology scanner is in final development. After obtaining CE IVDR certification, Vieworks plans to sign distribution agreements with leading dealers in key markets. The company expects these efforts to pave the way for entry into the global pathology market.
 

“The second-quarter results highlight balanced growth across all business lines alongside a recovery in profitability,” the official said. “With production capacity at our Hwaseong plant doubled in March and equipment setup now complete, operations are set to begin soon. The second half will mark a major turning point for capacity and supply flexibility.”

 

  • Listlist
  • Korean
  • English
  • Chinese
English